MetaCap

Lineage Cell Therapeutics Inc. Company Profile

NYSE: LCTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.7719-0.0481 (-5.87%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Lineage Cell Therapeutics at a glance

Lineage Cell Therapeutics Inc. (NYSE: LCTX) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Carlsbad, CA. Lineage Cell Therapeutics is led by Mr. Brian M. Culley M.A., M.B.A. and employs about 72 people. At a market capitalization of $195.3 million, it is considered a small-cap company.

Its SEC Central Index Key (CIK) is 0000876343, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Lineage Cell Therapeutics do?

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Business description based on the company's public filings.

Company information

Legal name
Lineage Cell Therapeutics Inc.
Ticker
NYSE: LCTX
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Brian M. Culley M.A., M.B.A.
Employees
72
Headquarters
2173 Salk Avenue, Carlsbad, CA, United States
Phone
442 287 8990
Market cap
$195.26M
SEC CIK
0000876343
Latest annual report
10-K · Mar 5, 2026

Companies similar to Lineage Cell Therapeutics

LCTX peer companies
CompanyPrice% ChgMarket capCompare
CABACabaletta Bio Inc.0.9361-7.32%$201.94Mvs LCTX
ARTVArtiva Biotherapeutics Inc.3.78-1.31%$186.85Mvs LCTX
IKTInhibikase Therapeutics Inc.1.32+1.54%$185.16Mvs LCTX
IPSCCentury Therapeutics Inc.1.17-11.74%$211.56Mvs LCTX
CGENCompugen Ltd.1.84-2.13%$174.29Mvs LCTX
ALLOAllogene Therapeutics Inc.0.6277-5.88%$217.48Mvs LCTX
SCTXScribe Therapeutics Inc.12.07-8.70%$228.58Mvs LCTX
PALIPalisade Bio Inc.0.8399-9.24%$150.74Mvs LCTX

Related